Role of targeted therapy in metastatic colorectal cancer

Colorectal cancer(CRC) is a significant cause of cancer-related morbidity and mortality all over the world.Improvements of cytotoxic and biologic agents have prolonged the survival in metastatic CRC(mC RC),with a median overall survival of approximately 2 years and more in the past two decades.The b...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastrointestinal oncology 2016-09, Vol.8 (9), p.642-655
Main Authors: Ohhara, Yoshihito, Fukuda, Naoki, Takeuchi, Satoshi, Honma, Rio, Shimizu, Yasushi, Kinoshita, Ichiro, Dosaka-Akita, Hirotoshi
Format: Article
Language:English
Subjects:
cancer
Aflibercept
Ramucirumab
Regorafenib
Cetuximab
Panitumumab
Targeted
colorectal
Metastatic
Review
therapy
Bevacizumab
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal cancer(CRC) is a significant cause of cancer-related morbidity and mortality all over the world.Improvements of cytotoxic and biologic agents have prolonged the survival in metastatic CRC(mC RC),with a median overall survival of approximately 2 years and more in the past two decades.The biologic agents that have proven clinical benefits in m CRC mainly target vascular endothelial growth factor(VEGF) and epidermal growth factor receptor(EGFR).In particular,bevacizumab targeting VEGF and cetuximab and panitumumab targeting EGFR have demonstrated sig-nificant survival benefits in combination with cytotoxic chemotherapy in the first-line,second-line,or salvage setting.Aflibercept,ramucirumab,and regorafenib are also used in second-line or salvage therapy.Recent retrospective analyses have shown that KRAS or NRAS mutations were negative predictive markers for anti-EGFR therapy.Based on the evidence from large rand-omized clinical trials,personalized therapy is necessary for patients with m CRC according to their tumor biology and characteristics.The aim of this paper was to summarize the results of the major randomized clinical trials and highlight the benefits of the molecular targeted agents in patients with mC RC.
ISSN:1948-5204
1948-5204
DOI:10.4251/wjgo.v8.i9.642